Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer
Open-label multicenter randomized Phase III trial.
Non-Small-Cell Lung Cancer
DRUG: Neoadjuvant chemotherapy (taxol and carboplatin)|DRUG: Adjuvant chemotherapy (taxol and carboplatin)|PROCEDURE: Surgery
Evaluate disease-free survival (DFS) and overall survival (OS), DFS: defined as the length of time from the date of diagnosis to the date of the first documented progression of disease OS: defined as the length of time from either the date of diagnosis or the start of the treatment that patients diagnosed with the disease are still alive., 5 years
Evaluate levels of response and the adverse effects of the chemotherapy, Occurrence and severity of adverse events, 5 years
Randomized trial of surgery with or without Paclitaxel (taxol) plus Carboplatin as neoadjuvant or adjuvant chemotherapy in patients with operable, non-small-cell lung cancer.